April 16, 2018

CytoReason Cements Proof-of-Concept with Machine-Learning-Facilitated Biomarker Breakthrough in Anti-TNFα Treatment Failure in Inflammatory Bowel Disease. New Data Published in Gut

TEL AVIV, Israel–(BUSINESS WIRE)–#Pharma–New data published in the prestigious BMJ journal, Gut, outlines the role of a new technological platform approach that has revealed a new blood-based biomarker that is 94% accurate in pretreatment identification of anti-TNFα non-responders in inflammatory bowel disease (IBD), accounting for approximately 30% of patients, confirming validity of the approach. The application of this platform led to the identification of the TREM1-CCR2-CCL7 axis (which manages t

Leave Comment

Your Name *
Your Email *
Your Website
Comment *